Full-Time

Clinical Specialist

Multiple Teams

Posted on 9/5/2025

Calyxo

Calyxo

201-500 employees

Develops and markets kidney stone devices

Compensation Overview

$100k - $140k/yr

+ Annual Variable Bonus + Auto Allowance + Cell Phone/Internet Allowance

No H1B Sponsorship

Fort Worth, TX, USA

Hybrid

Candidates must be based in the targeted geographical area.

Category
Medical, Clinical & Veterinary (1)
Required Skills
Sales
Marketing
Requirements
  • Clinical experience
  • Industry experience (1-3 years)
  • Prior Employment as a Clinical Specialist with a medical device company or experience working with Mobile Litho Provider Companies
  • Comfortable with the pace required to be successful in a start-up
  • Ability to provide intraoperative procedural guidance
  • Willingness to travel outside of the designated territory
  • Clinical experience: Intraoperative Coaching Experience
  • OR experience: Fluent in Staff and Support Training
  • Industry experience: 3+ years of full-time employment by a medical device company as a clinical specialist (or comparable position) focused on case coverage and patient outcomes (not equipment/service provider)
  • Track record of success. Urology experience preferred.
  • Willingness to travel outside of the designated territory
  • Experience in surgical technique and sterile procedures in the operating room
  • Experience utilizing fluoroscopy is a plus
  • Customer relationship and procedural skill development are highly desired
  • Highly desirable candidates will have a degree or certification in a medical-related field (ex: LPN, RN, Surg Tech, Rad Tech, etc)
  • Able to travel up to 80%
  • Compliance with relevant county, state, and federal rules regarding vaccinations
  • Ideal candidates will live in the targeted geographical area (Desirable)
Responsibilities
  • Provide clinical case coverage as assigned
  • Train the surgical team to assist in good patient outcomes and verbally support cases during training period
  • Acquire and maintain current knowledge of perioperative surgical technology practice and hospital policies and procedures
  • Develop technical acumen to a level to serve as an educational resource
  • Demonstrate appropriate interactions with all hospital service providers
  • Maintain and prepare equipment and kits for surgery, including Quality Control audits of equipment and kits
  • Troubleshoot equipment according to standard procedure
  • Provide intra-operative clinical product support
  • Ensure that 100% of received inventory and returned inventory matches shipping documents
  • Reconcile inventory/usage as well as missing inventory
  • Assist in the delivery of procedural training to physicians and medical staff
  • Be an effective member of the commercial team and play a key role in ensuring positive clinical outcomes
  • Support sales and marketing initiatives
  • Ensure compliance with all company policies, including the quality policy, on label promotion and interactions with health care professionals
  • Other duties as assigned
Desired Qualifications
  • Ideal candidates will live in the targeted geographical area
  • Experience utilizing fluoroscopy is a plus
  • Customer relationship and procedural skill development are highly desired
  • Highly desirable candidates will have a degree or certification in a medical-related field (ex: LPN, RN, Surg Tech, Rad Tech, etc)
  • Track record of success. Urology experience preferred.

Calyxo, Inc. develops medical devices for kidney stone treatment. Its products are designed for use by urologists in hospitals and clinics to treat kidney stones more effectively, prioritizing patient safety and efficient procedures. The company works closely with leading U.S. urologists to translate clinical needs into devices, focusing on making treatments safer and easier for clinicians. Unlike some competitors, Calyxo emphasizes clinician collaboration and proven clinical relevance in its device development, backed by leadership with startup and product-launch experience. The goal is to improve patient care by delivering advanced devices that help urologists achieve better clinical outcomes and expand the devices’ reach through commercialization to healthcare providers.

Company Size

201-500

Company Stage

Series F

Total Funding

$137.2M

Headquarters

Pleasanton, California

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • Series F raised $40M led by Ally Bridge Group and Janus Henderson Investors.
  • CVAC system treated over 40,000 patients, advancing toward standard of care.
  • ASPIRE study at AUA showed superior clearance independent of stone burden in 101 patients.

What critics are saying

  • Boston Scientific's LithoClast Trilogy erodes market share via hospital contracts in 12-24 months.
  • Cook Medical's NGage basket undercuts CVAC pricing by 30% in 12-18 months.
  • FDA Class I recall triggers withdrawal due to 5% ureteral perforation risks in 3-9 months.

What makes Calyxo unique

  • CVAC System integrates ureteroscopy, laser lithotripsy, irrigation, and aspiration in one device.
  • SURE procedure with CVAC achieves 97% volumetric stone clearance versus standard URS.
  • Redesigned CVAC received FDA clearance in March 2024 for minimally invasive treatment.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Stock Options

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

2%

2 year growth

8%
StreetInsider
Apr 14th, 2026
Calyxo raises $40M Series F as CVAC kidney stone system treats 40,000 patients

Calyxo, a medical device company focused on kidney stone treatment, has closed a $40 million Series F financing round led by Ally Bridge Group and Janus Henderson Investors. Questa Capital, Avidity Partners and CRG also participated. The funding follows a milestone of 40,000 patients treated with Calyxo's CVAC System, an aspiration-based stone removal device. The system uses irrigation and vacuum aspiration to continuously clear stone fragments during procedures, enabling more complete stone clearance. Proceeds will support commercial expansion, clinical evidence generation through ongoing studies evaluating long-term outcomes, and continued innovation in kidney stone care. The CVAC System received FDA clearance in 2024 and is positioned as an all-in-one solution for minimally invasive kidney stone removal.

Business Wire
May 14th, 2024
Study Presented At Aua Shows Superior Kidney Stone Clearance Rates For Sure Procedure Using Calyxo’S Cvac System Vs Standard Urs

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, has announced that positive study results for its CVAC System were presented last week at the American Urological Association (AUA) Annual Meeting in San Antonio. The CVAC System, a revolutionary technology that is designed for complete kidney stone removal, was the focus of the prospective, randomized, multi-center ASPIRE study, which compared the safety and efficacy of steerable ureteroscopic renal evacuation (SURE) vs ureteroscopy (URS) with basketing. The 30-day results of the ASPIRE study were presented at the AUA Meeting by urologist Thomas Chi, MD of the University of California, San Francisco. In 101 patients, SURE demonstrated statistically superior stone clearance and significantly lower residual stone volume compared to standard URS. Unlike standard URS, the CVAC System achieved these results independent of baseline stone burden. Safety was comparable between groups

Business Wire
Mar 26th, 2024
Calyxo Announces Fda Clearance For New, Redesigned Cvac System

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, announced that it has received FDA clearance for its new, redesigned CVAC System, which enables a minimally invasive approach to kidney stone treatment. More than 50 procedures have already been completed by 12 urologists with the new CVAC System, yielding strong patient outcomes and consistently positive physician feedback. Clinical studies have shown that residual stone fragments are associated with a 20%-44% incidence of post-procedure problems, including pain, infection, emergency department visits, hospitalization and need for retreatment. Steerable ureteroscopic renal evacuation (SURE) using the original CVAC Aspiration System has been used to successfully treat more than 1,500 patients in the U.S., demonstrating that vacuum aspiration of stone fragments improves clinical outcomes, with 97% volumetric stone clearance and a high likelihood of avoiding the need for a secondary or more invasive procedure (according to clinical study data collected in patients treated with the device)

FinSMEs
Dec 12th, 2023
Calyxo Raises $50M in Series D Funding

Calyxo, a Pleasanton, CA-based medical device company developing next-generation treatment solutions for patients with kidney stones, raised $50M in Series D funding.

Questa Capital
Jul 6th, 2022
Questa Capital invests into Calyxoinc in $32.7M

Calyxo, Inc., a medical device company focused on improving care for patients with kidney stones by delivering next generation treatment solutions, has announced the closing of a $32.7 million Series C financing round led by Questa Capital and CRG.

INACTIVE